Vontobel Holding Ltd. grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 229,111 shares of the biopharmaceutical company's stock after purchasing an additional 10,729 shares during the period. Vontobel Holding Ltd.'s holdings in Gilead Sciences were worth $25,672,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in GILD. FMR LLC grew its position in shares of Gilead Sciences by 21.6% during the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after buying an additional 7,157,113 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Gilead Sciences by 3.1% during the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock worth $3,293,822,000 after buying an additional 1,058,331 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Gilead Sciences by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock worth $2,608,337,000 after buying an additional 749,047 shares in the last quarter. Norges Bank acquired a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $1,789,254,000. Finally, Northern Trust Corp grew its position in shares of Gilead Sciences by 19.7% during the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after buying an additional 2,458,954 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.
Insider Activity at Gilead Sciences
In related news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the completion of the transaction, the chief executive officer owned 620,268 shares in the company, valued at $68,489,992.56. This represents a 1.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $275,425.00. Following the transaction, the chief financial officer owned 165,110 shares of the company's stock, valued at approximately $18,190,168.70. This trade represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold 58,500 shares of company stock worth $6,340,745 in the last 90 days. Corporate insiders own 0.27% of the company's stock.
Gilead Sciences Stock Performance
Shares of Gilead Sciences stock traded down $0.24 during trading on Friday, hitting $111.28. 4,039,811 shares of the stock were exchanged, compared to its average volume of 7,706,267. The stock's fifty day moving average is $107.02 and its 200 day moving average is $104.02. The stock has a market cap of $138.42 billion, a PE ratio of 23.43, a P/E/G ratio of 0.72 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences, Inc. has a 12 month low of $66.34 and a 12 month high of $119.96.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. Gilead Sciences's revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.32) EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a $0.79 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. Gilead Sciences's dividend payout ratio is presently 66.53%.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on GILD. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Morgan Stanley raised their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price for the company. Oppenheimer lowered their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and an average target price of $110.55.
Check Out Our Latest Stock Report on GILD
Gilead Sciences Company Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More

Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report